HCM
ADMS

Highlander Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Highlander Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,000
Closed -$21K – 767
2017
Q3 		$21K Buy
+1,000
New +$18.3K 0.02% 496

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Highlander Capital Management's ADMS Position: Q4 2017 in Review

Highlander Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2017, closing a stake of 1,000 shares — an estimated $21K sold.

Highlander Capital Management first reported a position in ADMS in Q3 2017 and held it in 1 quarter. The position peaked at $21K in Q3 2017. 117 funds tracked by Wall St. Rank hold ADMS as of Q4 2017.

  • Highlander Capital Management reported no remaining Adamas Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Highlander Capital Management sold 1,000 Adamas Pharmaceuticals shares in Q4 2017, an estimated $21K.
  • Highlander Capital Management first reported a position in Adamas Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Highlander Capital Management's Adamas Pharmaceuticals position peaked at $21K in Q3 2017.
  • 117 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2017.

Based on Highlander Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.